Live webinar discussion explored the benefits of ultra-sensitive detection for asymptomatic COVID-19 patients and highlighted linkages to other areas of human health BILLERICA, Mass. --(BUSINESS WIRE)--Sep. 20, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis

Simoa SARS-CoV-2 N Protein Antigen Test is first antigen test validated to detect all Variants of Concern currently designated by CDC , including Delta variant, and first authorized for use in saliva samples EUA label expansion demonstrates additional evidence showing potential for Simoa technology

BILLERICA, Mass. --(BUSINESS WIRE)--Sep. 10, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced a webinar hosted by Kevin Hrusovsky , Quanterix Chairman and Chief Executive Officer, with

BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 27, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today released the following statement in response to news reports related to Cassava Sciences.

BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 9, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman and Chief Executive Officer, Kevin Hrusovsky will participate in a virtual fireside chat discussion

Ultra-sensitive Simoa® HD-X technology powers new findings that detect rapid reduction of plasma P-tau217 from donanemab, Lilly’s investigational antibody therapy for Alzheimer's disease at 12 weeks BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 6, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company

Q2 GAAP revenue including Grant Revenue $25.4M ; Q2 Non-GAAP revenue $24.4M , an increase of 86% over prior year; instrument placements up 71% BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 5, 2021-- Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of

BILLERICA, Mass. --(BUSINESS WIRE)--Jul. 28, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for second quarter 2021 after the close of trading on Aug.

Doyle brings strong financial experience and track record to Quanterix BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 28, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has named

Ultra-sensitive biomarker platform delivers comprehensive evaluation of plasma NfL’s utility across 13 neurodegenerative disorders, Down syndrome and depression BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 7, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the